Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types.

Jiang, Shan; Deng, Xinzhou; Luo, Ming; Zhou, Le; Chai, Jingjing; Tian, Chao; Yan, Yutao; Luo, Zhiguo

Jiang, Shan; Deng, Xinzhou; Luo, Ming; Zhou, Le; Chai, Jingjing; Tian, Chao; Yan, Yutao; Luo, Zhiguo.

Afiliación

Jiang S; Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Deng X; Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Luo M; Hubei Key Laboratory of Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Zhou L; Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Chai J; Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Tian C; Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Yan Y; Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Luo Z; Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.

Front Oncol ; 13: 1207081, 2023.

Article en En | MEDLINE | ID: mdl-37746262

Palabras clave

OAS1; biomarker; pan-cancer; prognosis; tumor immune response

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google